TOPOLIVE 2.5 MG

Topotecan is linked in the source record to SCLC; Ovarian; Cervical, with the principal indications stated as Small cell lung cancer after relapse; ovarian and cervical cancers in selected settings. Its action is described as follows: Inhibits topoisomerase I, causing DNA single-strand breaks that become lethal during replication. Interference with topoisomerase-dependent DNA processing disrupts replication or chromosome handling, producing a cytotoxic effect in rapidly dividing malignant cells. Pharmacologically, it is a topoisomerase i inhibitor and is categorized as Chemotherapy; Topoisomerase Inhibitor. The regimen field identifies Topotecan monotherapy; platinum/topotecan regimens. The clinical importance of those combinations is that treatment partners can determine how the medicine is positioned within a larger oncology program. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. The indication should be read as a complete clinical statement, particularly where it contains receptor, mutation, stage, prior-treatment, or disease-status requirements. A class label alone cannot establish that a drug is appropriate for a particular patient or tumor. This entry provides an original reference summary based on the supplied clinical fields and does not substitute for current prescribing information. No individualized dose, dose adjustment, or administration instruction is included.